<p>Acute Coronary Syndrome (ACS) is a term used to describe a range of conditions that result from the sudden reduction or blockage of blood flow to the heart, leading to damage to the heart muscle. ACS includes conditions such as unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI). ACS is a medical emergency that requires rapid diagnosis and treatment to restore blood flow and prevent further damage to the heart. Key risk factors for ACS include hypertension, smoking, diabetes, high cholesterol, and a family history of heart disease.</p>
<h2><strong>Acute Coronary Syndrome Epidemiological Segmentation</strong></h2>
<p>The Epidemiological Segmentation of Acute Coronary Syndrome (ACS) in the 7MM (United States, EU5&mdash;Germany, France, Italy, Spain, and the United Kingdom&mdash;and Japan) from 2023 to 2034 includes:</p>
<ul>
<li>Total Incident Cases of ACS</li>
<li>Type-specific Incidence of ACS</li>
<li>Type-specific Incidence of Acute Myocardial Infarction (AMI)</li>
<li>Gender-specific Incidence of ACS</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/acute-coronary-syndrome-epidemiology-forecast"><span style="text-decoration: underline;"><strong>Acute Coronary Syndrome Epidemiology</strong></span></a></h2>
<ul>
<li>In 2023, the total incident cases of ACS in the United States were estimated to be approximately 1,306,700 cases, with an expected increase in incidence by 2034.</li>
<li>In EU4 and the UK, the total incident cases of ACS in 2023 were estimated at 514,410 cases for males and 269,750 cases for females.</li>
<li>In Japan, there were approximately 45,700 cases of STEMI and 34,500 cases of NSTEMI in 2023. These numbers are expected to rise by 2034.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/acute-coronary-syndrome-market"><span style="text-decoration: underline;"><strong>Acute Coronary Syndrome Market</strong></span></a></h2>
<p>The market size for ACS in the 7MM was approximately USD 2,670 million in 2023, with significant growth expected during the forecast period, driven by advances in treatment options and diagnostic technologies.</p>
<h2>Acute Coronary Syndrome Market Drivers</h2>
<ul>
<li>Advances in Treatment Options: The development of novel therapies for ACS, including antiplatelet agents, thrombolytics, and adjunctive treatments, is expected to fuel market growth.</li>
<li>Rising Incidence: As lifestyle factors and the aging population contribute to an increase in ACS cases, the demand for effective treatments and diagnostics will continue to rise.</li>
</ul>
<h2>Acute Coronary Syndrome Market Barriers</h2>
<ul>
<li>High Treatment Costs: The cost of managing ACS, including hospitalization, surgery, and long-term medications, may pose a barrier to market growth, particularly in low-resource settings.</li>
<li>Limited Access to Advanced Therapies: In some regions, access to the latest treatments and interventions for ACS may be limited due to healthcare infrastructure and cost barriers.</li>
</ul>
<h2><a href="https://www.delveinsight.com/report-store/acute-coronary-syndrome-pipeline-insight"><span style="text-decoration: underline;"><strong>Acute Coronary Syndrome Emerging Therapies</strong></span></a></h2>
<ul>
<li>Selatogrel (ACT-246475)</li>
<li>Dutogliptin</li>
<li>FARXIGA/FORXIGA (dapagliflozin)</li>
<li>FDY-5301</li>
<li>Dalcetrapib (RO4607381)</li>
<li>Vicagrel</li>
<li>Zalunfiban (RUC 4)</li>
<li>Ziltivekimab</li>
<li>Milvexian</li>
<li>ProtheraCytes</li>
<li>KAND567</li>
<li>Olpasiran</li>
<li>Orticumab</li>
</ul>
<p>and others</p>
<h2><a href="https://www.delveinsight.com/report-store/acute-coronary-syndrome-global-api-manufacturers-marketed-and-phase-iii-drugs-landscape"><span style="text-decoration: underline;"><strong>Acute Coronary Syndrome Key Players</strong></span></a></h2>
<ul>
<li>Idorsia Pharmaceuticals</li>
<li>Viatris</li>
<li>Recardio</li>
<li>AstraZeneca</li>
<li>Faraday Pharmaceuticals</li>
<li>DalCor Pharmaceuticals</li>
<li>Roche</li>
<li>Jiangsu Vcare PharmaTech</li>
<li>CeleCor Therapeutics</li>
<li>Novo Nordisk</li>
<li>Bristol Myers Squibb</li>
<li>Johnson &amp; Johnson Innovative Medicine</li>
<li>CellProthera</li>
<li>BioCardia</li>
<li>Kancera</li>
<li>Amgen</li>
<li>Arrowhead Pharmaceuticals</li>
<li>Abcentra</li>
</ul>
<p>and others</p>

Acute Coronary Syndrome  Market Infographic

Acute Coronary Syndrome  Market Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.